Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review

Kelly R. Culwell, Kathryn M. Curtis

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: As nearly all women with venous thromboembolism (VTE) will be treated with anticoagulant therapy, it is important to consider how anticoagulation affects the safety of contraceptive use. Study design: We conducted a systematic review of the literature regarding use of contraceptive methods in women with current VTE on anticoagulant therapy. Due to the limited direct evidence that was identified, we expanded our search to include women on anticoagulant therapy for indications other than VTE and women with bleeding disorders. Results: Six articles met our inclusion criteria. Three observational studies found the levonorgestrel-releasing IUD (LNG-IUD) was an effective treatment for menorrhagia for women on anticoagulation therapy or with bleeding disorders. Prevention of recurrent hemorrhagic ovarian cysts was seen in women on chronic anticoagulation treated with depot-medroxyprogesterone acetate (DMPA) in one small observational study. Among women with bleeding disorders, no complications were seen in 16 women with placement of the LNG-IUD. One pharmacokinetic study found no statistically significant interaction between combined oral contraceptives and warfarin. Other than one case report, no evidence was found regarding the risk of recurrent thrombosis in women on anticoagulation therapy using a contraceptive method. Conclusion: The majority of studies in this review examined treatment effects of the LNG-IUD or DMPA on complications of anticoagulation and found overall beneficial effects of their use in these circumstances. Minimal evidence in women with inherited bleeding disorders suggests that insertion of the LNG-IUD does not pose major bleeding risks in these women with appropriate management.

Original languageEnglish (US)
Pages (from-to)337-345
Number of pages9
JournalContraception
Volume80
Issue number4
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Contraception
Venous Thrombosis
Anticoagulants
Levonorgestrel
Hemorrhage
Venous Thromboembolism
Therapeutics
Medroxyprogesterone Acetate
Observational Studies
Contraceptives, Oral, Combined
Menorrhagia
Ovarian Cysts
Warfarin
Contraceptive Agents
Thrombosis
Pharmacokinetics
Safety

Keywords

  • Anticoagulants
  • Contraceptives
  • Venous thrombosis

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy : a systematic review. / Culwell, Kelly R.; Curtis, Kathryn M.

In: Contraception, Vol. 80, No. 4, 10.2009, p. 337-345.

Research output: Contribution to journalArticle

@article{3e1381a8c74d4ce88e6fc2a051840649,
title = "Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review",
abstract = "Background: As nearly all women with venous thromboembolism (VTE) will be treated with anticoagulant therapy, it is important to consider how anticoagulation affects the safety of contraceptive use. Study design: We conducted a systematic review of the literature regarding use of contraceptive methods in women with current VTE on anticoagulant therapy. Due to the limited direct evidence that was identified, we expanded our search to include women on anticoagulant therapy for indications other than VTE and women with bleeding disorders. Results: Six articles met our inclusion criteria. Three observational studies found the levonorgestrel-releasing IUD (LNG-IUD) was an effective treatment for menorrhagia for women on anticoagulation therapy or with bleeding disorders. Prevention of recurrent hemorrhagic ovarian cysts was seen in women on chronic anticoagulation treated with depot-medroxyprogesterone acetate (DMPA) in one small observational study. Among women with bleeding disorders, no complications were seen in 16 women with placement of the LNG-IUD. One pharmacokinetic study found no statistically significant interaction between combined oral contraceptives and warfarin. Other than one case report, no evidence was found regarding the risk of recurrent thrombosis in women on anticoagulation therapy using a contraceptive method. Conclusion: The majority of studies in this review examined treatment effects of the LNG-IUD or DMPA on complications of anticoagulation and found overall beneficial effects of their use in these circumstances. Minimal evidence in women with inherited bleeding disorders suggests that insertion of the LNG-IUD does not pose major bleeding risks in these women with appropriate management.",
keywords = "Anticoagulants, Contraceptives, Venous thrombosis",
author = "Culwell, {Kelly R.} and Curtis, {Kathryn M.}",
year = "2009",
month = "10",
doi = "10.1016/j.contraception.2009.04.008",
language = "English (US)",
volume = "80",
pages = "337--345",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy

T2 - a systematic review

AU - Culwell, Kelly R.

AU - Curtis, Kathryn M.

PY - 2009/10

Y1 - 2009/10

N2 - Background: As nearly all women with venous thromboembolism (VTE) will be treated with anticoagulant therapy, it is important to consider how anticoagulation affects the safety of contraceptive use. Study design: We conducted a systematic review of the literature regarding use of contraceptive methods in women with current VTE on anticoagulant therapy. Due to the limited direct evidence that was identified, we expanded our search to include women on anticoagulant therapy for indications other than VTE and women with bleeding disorders. Results: Six articles met our inclusion criteria. Three observational studies found the levonorgestrel-releasing IUD (LNG-IUD) was an effective treatment for menorrhagia for women on anticoagulation therapy or with bleeding disorders. Prevention of recurrent hemorrhagic ovarian cysts was seen in women on chronic anticoagulation treated with depot-medroxyprogesterone acetate (DMPA) in one small observational study. Among women with bleeding disorders, no complications were seen in 16 women with placement of the LNG-IUD. One pharmacokinetic study found no statistically significant interaction between combined oral contraceptives and warfarin. Other than one case report, no evidence was found regarding the risk of recurrent thrombosis in women on anticoagulation therapy using a contraceptive method. Conclusion: The majority of studies in this review examined treatment effects of the LNG-IUD or DMPA on complications of anticoagulation and found overall beneficial effects of their use in these circumstances. Minimal evidence in women with inherited bleeding disorders suggests that insertion of the LNG-IUD does not pose major bleeding risks in these women with appropriate management.

AB - Background: As nearly all women with venous thromboembolism (VTE) will be treated with anticoagulant therapy, it is important to consider how anticoagulation affects the safety of contraceptive use. Study design: We conducted a systematic review of the literature regarding use of contraceptive methods in women with current VTE on anticoagulant therapy. Due to the limited direct evidence that was identified, we expanded our search to include women on anticoagulant therapy for indications other than VTE and women with bleeding disorders. Results: Six articles met our inclusion criteria. Three observational studies found the levonorgestrel-releasing IUD (LNG-IUD) was an effective treatment for menorrhagia for women on anticoagulation therapy or with bleeding disorders. Prevention of recurrent hemorrhagic ovarian cysts was seen in women on chronic anticoagulation treated with depot-medroxyprogesterone acetate (DMPA) in one small observational study. Among women with bleeding disorders, no complications were seen in 16 women with placement of the LNG-IUD. One pharmacokinetic study found no statistically significant interaction between combined oral contraceptives and warfarin. Other than one case report, no evidence was found regarding the risk of recurrent thrombosis in women on anticoagulation therapy using a contraceptive method. Conclusion: The majority of studies in this review examined treatment effects of the LNG-IUD or DMPA on complications of anticoagulation and found overall beneficial effects of their use in these circumstances. Minimal evidence in women with inherited bleeding disorders suggests that insertion of the LNG-IUD does not pose major bleeding risks in these women with appropriate management.

KW - Anticoagulants

KW - Contraceptives

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=69949173529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949173529&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2009.04.008

DO - 10.1016/j.contraception.2009.04.008

M3 - Article

C2 - 19751856

AN - SCOPUS:69949173529

VL - 80

SP - 337

EP - 345

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -